Found this article earlier - IGF1 seems to be showing preliminary efficacy in another type of autism.
http://sfari.org/news-and-opinion/c...or-shows-promise-for-phelan-mcdermid-syndrome
Augurs well for nnz-2566.
If we can manage FDA approval for Rett, it really does open the doors across the autism spectrum - truly a class effect!
Wider autism efficacy potential for nnz-2566
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.42 |
Change
0.320(1.59%) |
Mkt cap ! $2.579B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $1.432M | 70.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 436 | $20.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.42 | 21 | 2 |
View Market Depth
| Last trade - 13.38pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |